These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 19429070

  • 1. PPARgamma stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells.
    Miglio G, Rattazzi L, Rosa AC, Fantozzi R.
    Neurosci Lett; 2009 Apr 24; 454(2):134-8. PubMed ID: 19429070
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.
    Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U.
    Toxicology; 2005 Sep 15; 213(1-2):157-68. PubMed ID: 16009482
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells.
    Oe T, Nagashima T, Muramoto M, Yamazaki T, Morikawa N, Okitsu O, Nishimura S, Aoki T, Katayama Y, Kita Y.
    Neuropharmacology; 2006 Jun 15; 50(8):1041-7. PubMed ID: 16574167
    [Abstract] [Full Text] [Related]

  • 9. Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells.
    Hellmann J, Rommelspacher H, Mühlbauer E, Wernicke C.
    Dev Neurosci; 2010 Mar 15; 32(1):33-46. PubMed ID: 19955695
    [Abstract] [Full Text] [Related]

  • 10. Suppression of proliferation and neurite extension of human neuroblastoma SH-SY5Y cells on immobilized Psathyrella velutina lectin.
    Kitamura N, Ikekita M, Hayakawa S, Funahashi H, Furukawa K.
    J Neurosci Res; 2004 Feb 01; 75(3):384-90. PubMed ID: 14743451
    [Abstract] [Full Text] [Related]

  • 11. TorsinA negatively controls neurite outgrowth of SH-SY5Y human neuronal cell line.
    Ferrari-Toninelli G, Paccioretti S, Francisconi S, Uberti D, Memo M.
    Brain Res; 2004 Jun 25; 1012(1-2):75-81. PubMed ID: 15158163
    [Abstract] [Full Text] [Related]

  • 12. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH-SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway.
    Alleaume C, Eychène A, Harnois T, Bourmeyster N, Constantin B, Caigneaux E, Muller JM, Philippe M.
    Exp Cell Res; 2004 Oct 01; 299(2):511-24. PubMed ID: 15350548
    [Abstract] [Full Text] [Related]

  • 13. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
    Oda T, Kume T, Izumi Y, Takada-Takatori Y, Niidome T, Akaike A.
    Eur J Pharmacol; 2008 Nov 19; 598(1-3):27-31. PubMed ID: 18835264
    [Abstract] [Full Text] [Related]

  • 14. The effect of benomyl on neurite outgrowth in mouse NB2A and human SH-SY5Y neuroblastoma cells in vitro.
    McLean WG, Holme AD, Janneh O, Southgate A, Howard CV, Reed MG.
    Neurotoxicology; 1998 Nov 19; 19(4-5):629-32. PubMed ID: 9745922
    [Abstract] [Full Text] [Related]

  • 15. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits neurite outgrowth in differentiating human SH-SY5Y neuroblastoma cells.
    Jung JE, Moon JY, Ghil SH, Yoo BS.
    Toxicol Lett; 2009 Jul 24; 188(2):153-6. PubMed ID: 19446249
    [Abstract] [Full Text] [Related]

  • 16. Vasoactive intestinal peptide-induced neuritogenesis in neuroblastoma SH-SY5Y cells involves SNAP-25.
    Héraud C, Chevrier L, Meunier AC, Muller JM, Chadéneau C.
    Neuropeptides; 2008 Jul 24; 42(5-6):611-21. PubMed ID: 18617262
    [Abstract] [Full Text] [Related]

  • 17. Retinoic acid differentiated SH-SY5Y human neuroblastoma cells: an in vitro model to assess drug neurotoxicity.
    Nicolini G, Miloso M, Zoia C, Di Silvestro A, Cavaletti G, Tredici G.
    Anticancer Res; 1998 Jul 24; 18(4A):2477-81. PubMed ID: 9703895
    [Abstract] [Full Text] [Related]

  • 18. IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.
    Pitulis N, Papageorgiou E, Tenta R, Lembessis P, Koutsilieris M.
    Anticancer Res; 2009 Jun 24; 29(6):2331-7. PubMed ID: 19528499
    [Abstract] [Full Text] [Related]

  • 19. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.
    Desouza CV, Gerety M, Hamel FG.
    Vascul Pharmacol; 2009 Jun 24; 51(2-3):162-8. PubMed ID: 19520186
    [Abstract] [Full Text] [Related]

  • 20. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 24; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.